GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update

GeoVax Labs Inc. (NASDAQ:GOVX) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 265,418 shares, a growth of 26.0% from the February 26th total of 210,698 shares. Approximately 14.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 69,667 shares, the days-to-cover ratio is presently 3.8 days.

GeoVax Labs Price Performance

Shares of NASDAQ:GOVX traded down $0.05 during trading on Monday, hitting $1.35. The company had a trading volume of 56,083 shares, compared to its average volume of 140,845. The stock has a market cap of $2.46 million, a price-to-earnings ratio of -0.04 and a beta of 3.81. The company has a fifty day simple moving average of $2.06 and a two-hundred day simple moving average of $7.87. GeoVax Labs has a one year low of $1.26 and a one year high of $34.75.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on GOVX. D. Boral Capital reaffirmed a “hold” rating on shares of GeoVax Labs in a report on Thursday, February 19th. Wall Street Zen lowered shares of GeoVax Labs to a “strong sell” rating in a report on Saturday, January 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a research note on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, GeoVax Labs has a consensus rating of “Hold” and an average target price of $187.50.

Institutional Investors Weigh In On GeoVax Labs

Several hedge funds and other institutional investors have recently made changes to their positions in GOVX. Sabby Management LLC bought a new position in GeoVax Labs during the 3rd quarter valued at about $313,000. Renaissance Technologies LLC purchased a new position in shares of GeoVax Labs during the fourth quarter valued at approximately $104,000. Jane Street Group LLC purchased a new position in shares of GeoVax Labs during the fourth quarter valued at approximately $99,000. Armistice Capital LLC bought a new position in shares of GeoVax Labs during the third quarter valued at approximately $253,000. Finally, HRT Financial LP purchased a new stake in shares of GeoVax Labs in the fourth quarter worth approximately $31,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.